Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Session 3: Therapeutic Applications II

Session 3: Therapeutic Applications II Human Antibodies 19 (2010) 35–37 DOI 10.3233/HAB-2010-0219 IOS Press Wednesday 14th April 2010. Moderator: Zdenka L. Jonak [14.00–14.30] ‘Development of therapeutic antibodies: Challenges and opportunities’ Yan Wu NovartisBiologics, Shanghai, China To date, the most difficult challenge to antibodybased therapy for a variety of diseases, particularly for cancer, is the balance of robust efficacy and minimal side effects on normal tissues. In the case of cancer intervention, it is highly desirable to have a therapeutics controlling metastasis that accounts for most death of cancer patients and enhancing antitumor immunity that is seriously weakened in patients with cancer. Antibody-directed therapeutics has been primarily focused on targeting a specific molecule that is functional in the pathogenesis of diseases. Antibody combination and bispecific antibody targeting disorder-associated cells or factors have been explored in the past years. Alternatively, the development of a therapeutic antibody targeting multiple molecules that involve in the pathogenesis and progression of one or more disease types will be also preferable. [14.30–14.50] ‘Clinical experience in a phase IIa trail with the human monoclonal IgM antibody Panobacumab in ventilator associated pneumonia caused by P.aeruginosa’ Michael Rudolf Kenta Biotech AG, Bern, Switzerland Kenta Biotech, founded in 2006 in Switzerland, is focusing on http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Human Antibodies IOS Press

Session 3: Therapeutic Applications II

Human Antibodies , Volume 19 (2) – Jan 1, 2010

Loading next page...
 
/lp/ios-press/session-3-therapeutic-applications-ii-jp0ro40zc2

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
IOS Press
Copyright
Copyright © 2010 by IOS Press, Inc
ISSN
1093-2607
eISSN
1875-869X
DOI
10.3233/HAB-2010-0219
Publisher site
See Article on Publisher Site

Abstract

Human Antibodies 19 (2010) 35–37 DOI 10.3233/HAB-2010-0219 IOS Press Wednesday 14th April 2010. Moderator: Zdenka L. Jonak [14.00–14.30] ‘Development of therapeutic antibodies: Challenges and opportunities’ Yan Wu NovartisBiologics, Shanghai, China To date, the most difficult challenge to antibodybased therapy for a variety of diseases, particularly for cancer, is the balance of robust efficacy and minimal side effects on normal tissues. In the case of cancer intervention, it is highly desirable to have a therapeutics controlling metastasis that accounts for most death of cancer patients and enhancing antitumor immunity that is seriously weakened in patients with cancer. Antibody-directed therapeutics has been primarily focused on targeting a specific molecule that is functional in the pathogenesis of diseases. Antibody combination and bispecific antibody targeting disorder-associated cells or factors have been explored in the past years. Alternatively, the development of a therapeutic antibody targeting multiple molecules that involve in the pathogenesis and progression of one or more disease types will be also preferable. [14.30–14.50] ‘Clinical experience in a phase IIa trail with the human monoclonal IgM antibody Panobacumab in ventilator associated pneumonia caused by P.aeruginosa’ Michael Rudolf Kenta Biotech AG, Bern, Switzerland Kenta Biotech, founded in 2006 in Switzerland, is focusing on

Journal

Human AntibodiesIOS Press

Published: Jan 1, 2010

There are no references for this article.